Fig 5. Dynamic changes of CgA levels during treatment.

(A), Patient 1 was treated with IP regimen for three months (6 cycles) with partial response (PR) followed by 6 months (6 cycles) of somatostatin analogues with progressive disease (PD) and 3 cycles of IP regimen with PR. (B), Patient 2 was treated with 6 cycles of IP regimen with PR followed by 3 cycles of SSAs with PD and 3 cycles of IP regimen with PD. Patient 3 (C) and patient 4 (D) were treated with 6 cycles of IP regimen with SD followed by 6 cycles of SSAs. Patient 5 (E) and patient 6 (F) were treated with 6 cycles of IP regimen followed by 6 cycles of SSAs.